Demyelination is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Demyelination is the pathological process of myelin sheath loss or damage surrounding neuronal axons in the central nervous system (CNS) or peripheral nervous system (PNS). Myelin, produced by [oligodendrocytes[/entities/[oligodendrocytes[/entities/[oligodendrocytes[/entities/[oligodendrocytes--TEMP--/entities)--FIX-- in the CNS and Schwann cells in the PNS, is essential for rapid saltatory conduction of electrical impulses, metabolic support of axons, and long-term axonal integrity. Loss of myelin disrupts neural signal transmission, leads to axonal vulnerability and degeneration, and is a core pathological feature of numerous neurodegenerative and neurological disorders (Franklin & Ffrench-Constant, 2017).
Demyelination is a central feature of [multiple sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis--TEMP--/diseases)--FIX-- and the leukodystrophies, but also contributes to pathology in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [Vascular Dementia[/diseases/[vascular-dementia[/diseases/[vascular-dementia[/diseases/[vascular-dementia--TEMP--/diseases)--FIX--, and other neurodegenerative conditions. Understanding the mechanisms of demyelination and the failure of remyelination is critical for developing therapies that halt or reverse neurodegeneration (Gao et al., 2025).
¶ Structure and Function
Myelin is a lipid-rich membrane that wraps around axons in multiple concentric layers. It is composed of approximately 70-80% lipid (predominantly cholesterol, galactocerebroside, and phospholipids) and 20-30% protein (including myelin basic protein [MBP[/genes/[mbp[/genes/[mbp[/genes/[mbp--TEMP--/genes)--FIX--, proteolipid protein [PLP], and myelin-associated glycoprotein [MAG). The myelin sheath is organized into internodal segments separated by nodes of Ranvier, where voltage-gated sodium channels cluster (Nave & Werner, 2014).
Key functions of myelin include:
- Saltatory conduction: Enables rapid nerve impulse propagation (up to 100 m/s in myelinated vs 1-2 m/s in unmyelinated fibers)
- Metabolic support: [oligodendrocytes[/entities/[oligodendrocytes[/entities/[oligodendrocytes[/entities/[oligodendrocytes--TEMP--/entities)--FIX-- provide lactate and other metabolites to axons through monocarboxylate transporters
- Axonal protection: Physical insulation protects axons from oxidative and inflammatory damage
- Trophic support: Myelin-derived signals promote axonal survival and caliber maintenance
In the CNS, [oligodendrocytes[/entities/[oligodendrocytes[/entities/[oligodendrocytes[/entities/[oligodendrocytes--TEMP--/entities)--FIX-- are the myelinating cells, with each oligodendrocyte capable of myelinating up to 50 axonal segments. Oligodendrocyte precursor cells (OPCs), also known as NG2 cells, represent 5-8% of all CNS cells and serve as the primary reservoir for remyelination throughout life.
Myelin is the direct target of the pathological process, with initial preservation of axons. This occurs in:
- [multiple sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis--TEMP--/diseases)--FIX--: Autoimmune-mediated destruction of myelin
- [Neuromyelitis Optica[/diseases/[neuromyelitis-optica[/diseases/[neuromyelitis-optica[/diseases/[neuromyelitis-optica--TEMP--/diseases)--FIX--: Aquaporin-4 antibody-mediated astrocyte and myelin damage
- Acute disseminated encephalomyelitis (ADEM): Post-infectious demyelination
- Progressive multifocal leukoencephalopathy (PML): JC virus infection of oligodendrocytes
Myelin loss occurs as a consequence of axonal degeneration or other primary pathology:
- [Wallerian Degeneration[/mechanisms/[wallerian-degeneration[/mechanisms/[wallerian-degeneration[/mechanisms/[wallerian-degeneration--TEMP--/mechanisms)--FIX--: Myelin breakdown following axonal transection
- Ischemic demyelination: From chronic hypoperfusion in [cerebral small vessel disease[/diseases/[cerebral-small-vessel-disease[/diseases/[cerebral-small-vessel-disease[/diseases/[cerebral-small-vessel-disease--TEMP--/diseases)--FIX-- and [Vascular Dementia[/diseases/[vascular-dementia[/diseases/[vascular-dementia[/diseases/[vascular-dementia--TEMP--/diseases)--FIX--
- Toxic/metabolic: Alcohol, chemotherapy agents, nutritional deficiencies
Genetic defects in myelin components or oligodendrocyte function lead to abnormal myelin formation:
- [Metachromatic Leukodystrophy[/diseases/[metachromatic-leukodystrophy[/diseases/[metachromatic-leukodystrophy[/diseases/[metachromatic-leukodystrophy--TEMP--/diseases)--FIX--: Arylsulfatase A deficiency
- [Krabbe Disease[/diseases/[krabbe-disease[/diseases/[krabbe-disease[/diseases/[krabbe-disease--TEMP--/diseases)--FIX--: Galactocerebroside beta-galactosidase deficiency
- [Pelizaeus-Merzbacher Disease[/diseases/[pelizaeus-merzbacher-disease[/diseases/[pelizaeus-merzbacher-disease[/diseases/[pelizaeus-merzbacher-disease--TEMP--/diseases)--FIX--: PLP1 mutations
- [Alexander Disease[/diseases/[alexander-disease[/diseases/[alexander-disease[/diseases/[alexander-disease--TEMP--/diseases)--FIX--: [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX-- mutations affecting astrocyte-oligodendrocyte interactions
- [Canavan Disease[/diseases/[canavan-disease[/diseases/[canavan-disease[/diseases/[canavan-disease--TEMP--/diseases)--FIX--: Aspartoacylase deficiency
- [Vanishing White Matter Disease[/diseases/[vanishing-white-matter[/diseases/[vanishing-white-matter[/diseases/[vanishing-white-matter--TEMP--/diseases)--FIX--: eIF2B mutations
- [Adrenoleukodystrophy[/diseases/[adrenoleukodystrophy[/diseases/[adrenoleukodystrophy[/diseases/[adrenoleukodystrophy--TEMP--/diseases)--FIX--: ABCD1 mutations affecting peroxisomal fatty acid metabolism
In autoimmune demyelinating diseases, the adaptive and innate immune systems attack myelin components:
- T cell-mediated: CD4+ Th1 and Th17 cells recognize myelin antigens and recruit inflammatory cells. CD8+ cytotoxic T cells directly attack oligodendrocytes
- Antibody-mediated: Anti-MOG and anti-AQP4 antibodies target myelin and [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--
- Complement activation: The [complement system[/entities/[complement-system[/entities/[complement-system[/entities/[complement-system--TEMP--/entities)--FIX-- mediates myelin opsonization and membrane attack complex (MAC)-mediated oligodendrocyte lysis
- [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX-- activation: Activated [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/entities/microgliahttps://doi.org/10.3389/fimmu.2017.00756))
¶ Oxidative and Nitrosative Stress
[reactive oxygen species[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- ([ROS[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- and reactive nitrogen species are particularly damaging to myelin:
- [oligodendrocytes[/entities/[oligodendrocytes[/entities/[oligodendrocytes[/entities/[oligodendrocytes--TEMP--/entities)--FIX-- are highly vulnerable to oxidative stress due to high metabolic demands, low antioxidant capacity, and high iron content
- Lipid peroxidation of myelin membranes disrupts membrane integrity
- Nitric oxide and peroxynitrite inhibit mitochondrial complex IV in oligodendrocytes
- [ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis--TEMP--/mechanisms)--FIX-- has been implicated in iron-dependent oligodendrocyte death
[glutamate[/entities/[glutamate[/entities/[glutamate[/entities/[glutamate--TEMP--/entities)--FIX---mediated [excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity--TEMP--/entities)--FIX-- damages both oligodendrocytes and myelin:
- Oligodendrocytes express AMPA and kainate receptors that are calcium-permeable
- Excess glutamate from activated [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/cell-types/microglia
Persistent demyelination leads to secondary axonal loss through multiple mechanisms (Trapp & Stys, 2009)):
- Energy failure: Redistributed sodium channels along demyelinated axons increase ATP demand for Na+/K+-ATPase activity, depleting axonal energy reserves
- Calcium overload: Energy failure leads to reverse operation of the sodium-calcium exchanger (NCX), causing intra-axonal calcium accumulation
- Calpain activation: Elevated calcium activates [calpains[/entities/[calpains[/entities/[calpains[/entities/[calpains--TEMP--/entities)--FIX-- and other proteases that degrade cytoskeletal proteins
- Loss of trophic support: Oligodendrocyte-derived metabolites (lactate, NAD+) essential for axonal survival are lost
- Mitochondrial damage: Chronic energy stress leads to [mitochondrial dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction[/mechanisms/[mitochondrial-dysfunction--TEMP--/mechanisms)--FIX-- and [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--
Progressive axonal loss eventually leads to retrograde neuronal degeneration. This is the pathological basis for progressive disability accumulation in [multiple sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis--TEMP--/diseases)--FIX-- and irreversible damage in leukodystrophies.
The CNS retains capacity for myelin repair throughout life, though efficiency declines with age:
- OPC activation: Injury signals (including growth factors, cytokines, and damage-associated molecular patterns) activate quiescent OPCs
- OPC recruitment: Activated OPCs proliferate and migrate toward demyelinated lesions, guided by chemokines (CXCL1, CXCL12) and growth factors (PDGF, FGF2)
- OPC differentiation: OPCs differentiate into mature oligodendrocytes, a process requiring downregulation of inhibitory signals (Wnt, Notch, LINGO-1) and upregulation of pro-differentiation transcription factors (Olig2, Myrf, Sox10)
- Remyelination: New oligodendrocytes extend processes and wrap demyelinated axons, producing thinner myelin sheaths than the original (visible histologically as "shadow plaques" in MS)
Multiple factors impede successful remyelination (Franklin & Ffrench-Constant, 2017):
- OPC differentiation block: The most critical failure point. OPCs are often present in chronic MS lesions but fail to mature into myelinating oligodendrocytes
- Inhibitory extracellular matrix: Chondroitin sulfate proteoglycans (CSPGs), hyaluronan, and fibronectin in chronic lesions inhibit OPC differentiation
- Dysregulated signaling: Persistent activation of Wnt/β-catenin, Notch, and BMP pathways blocks OPC maturation
- Aging: Reduced OPC proliferative capacity, impaired macrophage function (failure to clear myelin debris), and epigenetic changes that silence pro-differentiation genes
- Chronic inflammation: Sustained [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX-- creates a hostile environment for remyelination
- Axonal damage: Severely damaged axons cannot support remyelination
Promoting remyelination is a major therapeutic goal (Gao et al., 2025):
Signaling Pathway Modulators:
- Anti-LINGO-1 antibodies (opicinumab): Block LINGO-1, a negative regulator of OPC differentiation
- Wnt pathway inhibitors: Relieve Wnt-mediated differentiation block
- Muscarinic receptor antagonists (clemastine, benzatropine): Promote OPC differentiation
Growth Factors and Cytokines:
- CNTF/LIF mimetics: CNS-penetrating Fc-fusion proteins to promote oligodendrocyte survival and differentiation
- [BDNF[/entities/[bdnf[/entities/[bdnf[/entities/[bdnf--TEMP--/entities)--FIX--: Promotes both neuronal survival and OPC maturation
ECM Modifiers:
- Chondroitinase ABC nanoparticles: Degrade inhibitory CSPGs in chronic lesions
- Laminin/fibronectin hydrogels: Provide pro-myelination matrix signals
Transcription Factor Targets:
- Myt1L: Essential regulator of OPC differentiation (Kim et al., 2018)
- TCF7L2: Downstream Wnt effector whose targeting enhances oligodendrocyte differentiation
Cell-Based Therapies:
- OPC transplantation: Directly replace lost myelinating cells
- [Stem cell therapy[/treatments/[stem-cell-therapy[/treatments/[stem-cell-therapy[/treatments/[stem-cell-therapy--TEMP--/treatments)--FIX--: iPSC-derived OPCs for autologous transplantation
- Netrin-1-secreting OPC grafts: Enhance endogenous oligodendrogenesis
White matter degeneration and myelin loss are now recognized as early features of [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, not merely secondary to cortical neuronal loss:
- Myelin breakdown products are elevated in CSF years before clinical symptom onset
- Oligodendrocyte vulnerability to [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- toxicity and [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--
- White matter hyperintensities (a marker of demyelination) predict conversion from MCI to AD
- [Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- pathology] in white matter disrupts axon-oligodendrocyte interactions
- Single-cell transcriptomic studies reveal oligodendrocyte subtypes preferentially lost in AD
[Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- shows selective white matter changes:
- Reduced myelin content in frontal and parietal white matter tracts
- [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- inclusions in oligodendrocytes (particularly in [MSA)
- Correlation between white matter integrity loss and cognitive decline
[ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- involves oligodendrocyte pathology and demyelination in motor tracts:
- Oligodendrocyte degeneration precedes motor neuron loss in animal models
- [SOD1[/proteins/[sod1-protein[/proteins/[sod1-protein[/proteins/[sod1-protein--TEMP--/proteins)--FIX-- mutations cause direct oligodendrocyte toxicity
- MCT1 (monocarboxylate transporter 1) downregulation in oligodendrocytes reduces metabolic support to motor neuron axons
[Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- shows prominent white matter changes:
- Early white matter volume loss, detectable years before symptom onset
- Mutant [huntingtin protein[/proteins/[htt-protein[/proteins/[htt-protein[/proteins/[htt-protein--TEMP--/proteins)--FIX-- disrupts oligodendrocyte maturation and myelin gene expression
- [Striatal] white matter tract degeneration correlates with motor and cognitive decline
- [Astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--
- [Oligodendrocytes[/cell-types/[oligodendrocytes[/cell-types/[oligodendrocytes[/cell-types/[oligodendrocytes--TEMP--/cell-types)--FIX--
The study of Demyelination has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Franklin, R. J. M., & Ffrench-Constant, C. (2017). Regenerating CNS myelin — from mechanisms to experimental medicines. Nature Reviews Neuroscience, 18(12), 753–769. DOI
- [Nave, K. A., & Werner, H. B. (2014). Myelination of the nervous system: mechanisms and functions. Annual Review of Cell and Developmental Biology, 30, 503–533. DOI
- [Trapp, B. D., & Stys, P. K. (2009). Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. The Lancet Neurology, 8(3), 280–291. DOI
- [Gao, X., et al. (2025). Oligodendrocyte precursor cells in demyelination repair: Mechanisms, crosstalk, and therapeutic frontiers. Medicine Bulletin. DOI)
- [Kim, J. G., et al. (2018). Myt1L promotes differentiation of oligodendrocyte precursor cells and is necessary for remyelination after lysolecithin-induced demyelination. Neuroscience, 370, 78–86. PMC)
- [Luo, C., et al. (2017). The role of [microglia[/[DOI[/[DOI[/[DOI[/[DOI[/[DOI[/DOI(https://doi.org/10.3389/fimmu.2017.00756)
- [Lassmann, H., van Horssen, J., & Mahad, D. (2012). Progressive multiple sclerosis: pathology and pathogenesis. Nature Reviews Neurology, 8(11), 647–656. DOI
- [Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002). Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. New England Journal of Medicine, 346(3), 165–173. DOI
- [Kuhlmann, T., Miron, V., Cui, Q., et al. (2008). Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain, 131(7), 1749–1758. DOI
- [Lee, Y., Morrison, B. M., Li, Y., et al. (2012). Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature, 487(7408), 443–448. DOI
- [Saab, A. S., Tzvetavona, I. D., Trevisiol, A., et al. (2016). Oligodendroglial [NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptors regulate glucose import and axonal energy metabolism. [Neuron[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, 91(4), 884–895. DOI
- [Deshmukh, V. A., Tardif, V., Bhatt, D. K., et al. (2013). A regenerative approach to the treatment of multiple sclerosis. Nature, 502(7471), 327–332. DOI
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
12 references |
| Replication |
0% |
| Effect Sizes |
50% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
75% |
Overall Confidence: 45%